In this review, we have presented the evidence for the beneficial effect of glucagon-like peptide-1 receptor agonists on diabetic nephropathy and detailed the underlying molecular mechanisms involved in its pathophysiology. The gene discussed is GLP1R; the disease is diabetic kidney disease.